Danaher (DHR) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

Danaher (DHR) reported $5.94 billion in revenue for the quarter ended June 2025, representing a year-over-year increase of 3.4%. EPS of $1.80 for the same period compares to $1.72 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $5.84 billion, representing a surprise of +1.71%. The company delivered an EPS surprise of +9.76%, with the consensus EPS estimate being $1.64.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.Here is how Danaher performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:Total Growth - Organic sales (Core): 1.5% versus the three-analyst average estimate of 1.5%.Total sales- Diagnostics: $2.31 billion versus $2.28 billion estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +2.2% change.Total sales- Life Sciences: $1.78 billion compared to the $1.71 billion average estimate based on three analysts. The reported number represents a change of +0.4% year over year.Total sales- Biotechnology: $1.85 billion versus $1.83 billion estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +8% change.Operating profit- Life Sciences: $-239 million versus the two-analyst average estimate of $206.51 million.Operating profit- Biotechnology: $531 million compared to the $463.69 million average estimate based on two analysts.Operating profit- Other: $-86 million versus $-77.91 million estimated by two analysts on average.Operating profit- Diagnostics: $554 million compared to the $501.31 million average estimate based on two analysts.View all Key Company Metrics for Danaher here>>>Shares of Danaher have returned -4.2% over the past month versus the Zacks S&P 500 composite's +5.9% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.Zacks' Research Chief Names "Stock Most Likely to Double"Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Danaher Corporation (DHR): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks